Low dose morphine adjuvant therapy for enhanced efficacy of antipsychotic drug action: Potential involvement of endogenous morphine in the pathophysiology of schizophrenia

Medical Science Monitor

Volumn 18, Issue 7, 2012, Pages

  Stefano, George B ^a   Králíčková, Milena ^b   Ptacek, Radek ^b   Kuzelova, Hana ^b   Esch, Tobias ^a,c   Kream, Richard M ^a  

^a STATE UNIVERSITY OF NEW YORK   (United States)

^b CHARLES UNIVERSITY   (Czech Republic)

^c Robotics Research Lab   (Germany)

Author keywords

Antipsychotic drugs; Dopamine; Morphine; Mu opioid receptors; Nicotinic receptors; Schizophrenia; Serotonin

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CARFENTANIL; DOPAMINE RECEPTOR; HYDROCORTISONE; MORPHINE; MU OPIATE RECEPTOR; NEUROLEPTIC AGENT; NICOTINIC RECEPTOR; OLANZAPINE; OXYCODONE; PLACEBO; PROLACTIN; SEROTONIN RECEPTOR;

ADJUVANT THERAPY; AMYGDALOID NUCLEUS; ANALGESIA; ANTERIOR CINGULATE; ANTINOCICEPTION; ARTICLE; ATTENTION; BRAIN SIZE; COGNITION; CORPUS STRIATUM; DISEASE SEVERITY; DOPAMINERGIC TRANSMISSION; DORSAL RAPHE NUCLEUS; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DSM-IV; EMOTION; EXECUTIVE FUNCTION; FRONTAL CORTEX; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GRAY MATTER; HIPPOCAMPUS; HUMAN; HYDROCORTISONE BLOOD LEVEL; IN VITRO STUDY; IN VIVO STUDY; INSULA; LIGAND BINDING; LOW DRUG DOSE; MENTAL TASK; META ANALYSIS (TOPIC); METABOLIC DISORDER; MOTOR PERFORMANCE; NOCICEPTION; OFF LABEL DRUG USE; ORBITAL CORTEX; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PAIN; PREFRONTAL CORTEX; PREPULSE INHIBITION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SENSORY GATING; SIDE EFFECT; SINGLE DRUG DOSE; STARTLE REFLEX; TREATMENT DURATION; VERBAL COMMUNICATION; VERBAL MEMORY; WEIGHT GAIN; WORKING MEMORY;

EID: 84863790754     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.883192     Document Type: Article

References (33)

1. Meltzer HY, Li Z, Kaneda Y, Ichikawa J: Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry, 2003; 27: 1159-72
2. Kuroki T, Nagao N, Nakahara T: Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. Prog Brain Res, 2008; 172: 199-212
3. Meltzer HY, Huang M: In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog Brain Res, 2008; 172: 177-97
4. Richtand NM, Welge JA, Logue AD et al: Role of serotonin and dopa mine receptor binding in antipsychotic efficacy. Prog Brain Res, 2008; 172: 155-75
5. Alexander GC, Gallagher SA, Mascola A et al: Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf, 2011; 20: 177-84
6. Komossa K, Rummel-Kluge C, Hunger H et al: Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev, 2010; CD006654
7. Citrome L: A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia. Expert Opin Pharmacother, 2011 [Epub ahead of print]
8. Bralet MC, Navarre M, Eskenazi AM et al: [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)]. Encephale, 2008; 34: 557-62
9. Semkovska M, Bedard MA, Stip E: [Hypofrontality and negative symptoms in schizophrenia: synthesis of anatomic and neuropsychological knowledge and ecological perspectives]. Encephale, 2001; 27: 405-15
10. Minzenberg MJ, Laird AR, Thelen S et al: Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia. Arch Gen Psychiatry, 2009; 66: 811-22
11. Stip E: [Cognition, schizophrenia and the effect of antipsychotics]. Encephale, 2006; 32: 341-50
12. Quednow BB, Csomor PA, Chmiel J et al: Sensorimotor gating and attentional set-shifting are improved by the mu-opioid receptor agonist morphine in healthy human volunteers. Int J Neuropsychopharmacol, 2008; 11: 655-69
13. Li L, Du Y, Li N et al: Top-down modulation of prepulse inhibition of the startle reflex in humans and rats. Neurosci Biobehav Rev, 2009; 33: 1157-67
14. Kumari V, Fannon D, Geyer MA et al: Cortical grey matter volume and sensorimotor gating in schizophrenia. Cortex, 2008; 44: 1206-14
15. Becerra L, Harter K, Gonzalez RG, Borsook D: Functional magnetic resonance imaging measures of the effects of morphine on central nervous system circuitry in opioid-naive healthy volunteers. Anesth Analg, 2006; 103: 208-16
16. Raja SN, Haythornthwaite JA, Pappagallo M et al: Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology, 2002; 59: 1015-21
17. Fong HK, Sands LP, Leung JM: The role of postoperative analgesia in delirium and cognitive decline in elderly patients: a systematic review. Anesth Analg, 2006; 102: 1255-66
18. Cherrier MM, Amory JK, Ersek M et al: Comparative cognitive and subjective side effects of immediate-release oxycodone in healthy middleaged and older adults. J Pain, 2009; 10: 1038-50
19. Oken BS: Placebo effects: clinical aspects and neurobiology. Brain, 2008; 131: 2812-23
20. Zubieta JK, Stohler CS: Neurobiological mechanisms of placebo responses. Ann NY Acad Sci, 2009; 1156: 198-210
21. Wager TD, Scott DJ, Zubieta JK: Placebo effects on human mu-opioid activity during pain. Proc Natl Acad Sci USA, 2007; 104: 11056-61
22. Harris RE, Zubieta JK, Scott DJ et al: Traditional Chinese acupuncture and placebo (sham) acupuncture are differentiated by their effects on mu-opioid receptors (MORs). Neuroimage, 2009; 47: 1077-85
23. Atlas LY, Bolger N, Lindquist MA, Wager TD: Brain mediators of predictive cue effects on perceived pain. J Neurosci, 2010; 30: 12964-77
24. Hautzel H, Muller HW, Herzog H, Grandt R: Cognition-induced modulation of serotonin in the orbitofrontal cortex: a controlled cross-over PET study of a delayed match-to-sample task using the 5-HT2a receptor antagonist [18F]altanserin. Neuroimage, 2011; 58: 905-11
25. Rasmussen H, Erritzoe D, Andersen R et al: Decreased frontal serotonin2A receptor binding in antipsychotic-naive patients with first-episode schizophrenia. Arch Gen Psychiatry, 2010; 67: 9-16
26. Quednow BB, Treyer V, Hasler F et al: Assessment of serotonin release capacity in the human brain using dexfenfluramine challenge and [(18) F]altanserin positron emission tomography. Neuroimage, 2012; 59(4): 3922-32
27. Lopez-Gimenez JF, Vilaro MT, Milligan G: Morphine desensitization, internalization, and down-regulation of the mu opioid receptor is facilitated by serotonin 5-hydroxytryptamine2A receptor coactivation. Mol Pharmacol, 2008; 74: 1278-91
28. Petrovsky N, Quednow BB, Ettinger U et al: Sensorimotor gating is associated with CHRNA3 polymorphisms in schizophrenia and healthy volunteers. Neuropsychopharmacology, 2010; 35: 1429-39
29. Ferezou I, Hill EL, Cauli B et al: Extensive overlap of mu-opioid and nicotinic sensitivity in cortical interneurons. Cereb Cortex, 2007; 17: 1948-57
30. Stefano GB, Kream RM, Mantione KJ, Ptacek R: Endogenous morphine, stress and psychiatric disorders review of actual findings. Journal of Czech Psychology, 2011; In Press
31. Kream RM, Stefano GB: Schizophrenia: Comorbidity and/or Self Medication. Biomedical Papers, 2011; In Press
32. Bianchi E, Guarna M, Tagliamonte A: Immunocytochemical localization of endogenous codeine and morphine. Adv Neuroimmunol, 1994; 4: 83-92
33. Glattard E, Welters ID, Lavaux T et al: Endogenous morphine levels are increased in sepsis: a partial implication of neutrophils. PLoS One, 2010; 5: e8791